Founded by Professor Simone Spuler and Dr. Verena Schöwel-Wolf, MyoPax emerged from years of research at Charité – Universitätsmedizin Berlin and the Max Delbrück Center. The team focuses on developing innovative autologous muscle stem cell therapies to treat loss of muscle function resulting from trauma, disease-related procedures, or critical genetic conditions. They seek to restore muscle function and improve the lives of the patients.
At the core of MyoPax is a patented method for isolating and cultivating highly regenerative muscle stem cells, PHSats (Primary Human Satellite cell derived muscle stem cell), enabling the production of large, high-purity populations of muscle stem cells for therapeutic use.
SPARK-BIH supported the team from the very beginning on its path from academic research toward clinical application.
Over the years, MyoPax has achieved numerous important milestones. For example, in 2022, the team secured €1.3 million in funding through the BioInnovation Institute in Copenhagen, in 2023, they were granted the FDA Rare Pediatric Disease Designation and Orphan Drug Designation for their regenerative therapy targeting Exstrophy-Epispadias Complex (EEC), a rare congenital disorder affecting bladder muscle development in children, and in 2024, they entered the Bayer Co.Lab.
Today, MyoPax is developing cell and gene therapies bringing new hope to patients with previously untreatable muscle diseases.
For the SPARK-BIH team, MyoPax is a clear example of how promising academic research can evolve into solutions with real potential for patients.
